PubMed

Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.

Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.

Diabetes Care. 2008 May;31(5):852-6. Epub 2008 Feb 11.PMID: 18268073 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.PMID: 18158078 [PubMed - indexed for MEDLINE]Related articles

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; INITIATE Study Group.

Diabetes Care. 2005 Feb;28(2):260-5.PMID: 15677776 [PubMed - indexed for MEDLINE]Related articlesFree article

Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).

Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.

Diabetes Obes Metab. 2006 Jan;8(1):58-66.PMID: 16367883 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group.

Curr Med Res Opin. 2009 Jan;25(1):65-75.PMID: 19210140 [PubMed - indexed for MEDLINE]Related articles

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.

Diabetes Obes Metab. 2009 Jan;11(1):27-32. Epub 2007 Oct 17.PMID: 17941873 [PubMed - indexed for MEDLINE]Related articles

Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.

Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.

Diabetes Obes Metab. 2008 Mar;10(3):229-37.PMID: 18269638 [PubMed - indexed for MEDLINE]Related articles

Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.

Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M.

Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):527-32.PMID: 17115351 [PubMed - indexed for MEDLINE]Related articles

Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.

Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.

Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):511-9.PMID: 17115349 [PubMed - indexed for MEDLINE]Related articles

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

Hollander P, Cooper J, Bregnhøj J, Pedersen CB.

Clin Ther. 2008 Nov;30(11):1976-87.PMID: 19108786 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.

Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J.

Clin Ther. 2005 Sep;27(9):1432-43.PMID: 16291416 [PubMed - indexed for MEDLINE]Related articles

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.

Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A.

Diabet Med. 2002 May;19(5):393-9. Erratum in: Diabet Med. 2002 Sep;19(9):797.. PMID: 12027927 [PubMed - indexed for MEDLINE]Related articles

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

Ann Intern Med. 2005 Oct 18;143(8):559-69.PMID: 16230722 [PubMed - indexed for MEDLINE]Related articlesFree article

Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.

Gao Y, Guo XH, Vaz JA; PRESENT Study Group.

Diabetes Obes Metab. 2009 Jan;11(1):33-40. Epub 2008 May 20. Erratum in: Diabetes Obes Metab. 2009 Jan;11(1):77. PMID: 18494806 [PubMed - indexed for MEDLINE]Related articles

A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P.

Diabetes Care. 2006 Jun;29(6):1269-74. Erratum in: Diabetes Care. 2007 Apr;30(4):1035. PMID: 16732007 [PubMed - indexed for MEDLINE]Related articlesFree article

Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.

Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I.

Diabetes Obes Metab. 2003 Nov;5(6):446-54.PMID: 14617231 [PubMed - indexed for MEDLINE]Related articles

Biphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: a retrospective case series analysis from clinical practice.

Tibaldi JT.

Adv Ther. 2007 Nov-Dec;24(6):1348-56.PMID: 18165218 [PubMed - indexed for MEDLINE]Related articles

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.

Diabetes Care. 2005 Feb;28(2):254-9.PMID: 15677775 [PubMed - indexed for MEDLINE]Related articlesFree article